Use of bevacizumab in a patient with Whipple's disease: managing diagnostic uncertainty

BMJ Case Rep. 2023 Oct 24;16(10):e256460. doi: 10.1136/bcr-2023-256460.

Abstract

A man in his 30s with intellectual disability presented with 1 month of diarrhoea, weight loss and dyspnoea. Investigations were hampered due to significant anxiety. Laboratory tests detected microcytic anaemia and hypoalbuminaemia. CT demonstrated a fat-containing infiltrate in the mediastinum, mesentery and axillae, and pulmonary ground-glass infiltrates. Biopsy of the axilla showed cystic lymphatic malformations involving adipose tissue and lymph nodes, leading to a provisional diagnosis of generalised lymphatic anomaly. Over the subsequent 4 months, the patient's respiratory status deteriorated, leading to type 1 respiratory failure necessitating intubation. After multidisciplinary discussion, a decision was made to trial bevacizumab, an anti-VEGF agent, with subsequent improvement in respiratory status. While intubated, gastroscopy was performed; duodenal biopsies revealed pathognomonic changes of Whipple's disease, confirmed on PCR of duodenal and axillae biopsies. This was deemed the most likely unifying diagnosis; antibiotic treatment was commenced, bevacizumab was ceased, and the patient has remained well after 18 months.

Keywords: Endoscopy; Gastrointestinal system; Infection (gastroenterology); Infections.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Bevacizumab* / therapeutic use
  • Biopsy
  • Humans
  • Male
  • Uncertainty
  • Whipple Disease* / drug therapy
  • Whipple Disease* / pathology

Substances

  • Anti-Bacterial Agents
  • Bevacizumab